Information Provided By:
Fly News Breaks for December 19, 2019
CDNA, NTRA
Dec 19, 2019 | 09:32 EDT
Centers for Medicare and Medicaid published the final Medicare coverage decision for Prospera, Natera's kidney transplant rejection test, Craig-Hallum analyst Alexander Nowak tells investors in a research note. There was no change to the language from the draft decision and patients will be covered under Medicare effective February 3, the analyst points out. If Natera is successful recruiting patients outside the registry trial, then he sees upside to estimates. However, given the existing data today compared to incumbent CareDx (CDNA), CareDx believes only modeling registry trial sales at this point is prudent. Nonetheless, he reiterates a Buy rating on Natera shares with a $49 price target saying the final coverage is good for the company.
News For NTRA;CDNA From the Last 2 Days
There are no results for your query NTRA;CDNA